Literature DB >> 21719569

Isoliquiritigenin from licorice root suppressed neovascularisation in experimental ocular angiogenesis models.

Vishal Jhanji1, Huanming Liu, Kasin Law, Vincent Yau-Wing Lee, Shao-Fen Huang, Chi-Pui Pang, Gary Hin-Fai Yam.   

Abstract

AIM: To explore the antiangiogenic property of isoliquiritigenin (ISL) on in vivo and in vitro models.
DESIGN: Laboratory investigation.
METHODS: The effect of ISL on angiogenesis development was investigated using ex ovo chick chorioallantoic membrane model. Its effect on pathological angiogenesis was examined by (1) silver nitrate cauterisation-induced corneal neovascularisation in BALB/c mice, followed by topical ISL (0.2-50 μM) and CD31 immunofluorescence of corneal blood vessels; (2) argon laser photocoagulation-induced choroidal neovascularisation in C57BL/6 mice, followed by intravitreal ISL (10-200 μM) and fundus fluorescein angiography and immunofluorescence with Griffonia simplicifolia isolectin-B4 (GSA I-B4); and (3) oxygen-induced retinopathy in C57BL/6J mice pups, followed by intravitreal ISL (1-100 μM) and GSA I-B4 immunofluorescence. The vascular area was quantified and analysed by one-way analysis of variance and Student t test. Expression of vascular endothelial growth factor (VEGF) and pigment-epithelium-derived factor in human umbilical vein endothelial cells was analysed by western blotting.
RESULTS: Ex ovo chick chorioallantoic membrane assay showed that ISL dose-dependently suppressed VEGF-induced vessel growth. In vivo experiments illustrated that topical ISL alleviated corneal neovascularisation (IC(50)=7.14 μM, day 7) and intravitreal ISL reduced vessel leakage and GSA I-B4-positive vascular area in choroidal and retinal neovascularisation. ISL was found to dose-dependently suppress VEGF and induce pigment epithelium derived factor expression in cultured endothelial cells.
CONCLUSION: Using various experimental models of ocular neovascularisation, the authors have demonstrated that ISL from licorice extract has an antiangiogenic effect. The authors' findings suggest that ISL may be a potential antiangiogenic molecule in the development of therapy for neovascularisation diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719569     DOI: 10.1136/bjophthalmol-2011-300110

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  A comparing study of quantitative staining techniques for retinal neovascularization in a mouse model of oxygen-induced retinopathy.

Authors:  Xiao-Ling Liang; Jie Li; Fang Chen; Xiao-Yan Ding; Xiu-Xia Yang; Liao-Xu Long
Journal:  Int J Ophthalmol       Date:  2012-02-18       Impact factor: 1.779

2.  Preparation and in vitro and in vivo evaluation of an isoliquiritigenin-loaded ophthalmic nanoemulsion for the treatment of corneal neovascularization.

Authors:  Rui Zhang; Jingjing Yang; Qing Luo; Jieran Shi; Haohang Xu; Junjie Zhang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 3.  Natural product inhibitors of ocular angiogenesis.

Authors:  Rania S Sulaiman; Halesha D Basavarajappa; Timothy W Corson
Journal:  Exp Eye Res       Date:  2014-10-07       Impact factor: 3.467

4.  Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth.

Authors:  Brian C Stagg; Hironori Uehara; Nathan Lambert; Ruju Rai; Isha Gupta; Bryce Radmall; Taylor Bates; Balamurali K Ambati
Journal:  Cancers (Basel)       Date:  2014-11-26       Impact factor: 6.639

Review 5.  Antiangiogenic Effect of Flavonoids and Chalcones: An Update.

Authors:  Ladislav Mirossay; Lenka Varinská; Ján Mojžiš
Journal:  Int J Mol Sci       Date:  2017-12-22       Impact factor: 5.923

Review 6.  A Critical Analysis of the Available In Vitro and Ex Vivo Methods to Study Retinal Angiogenesis.

Authors:  A F Moleiro; G Conceição; A F Leite-Moreira; A Rocha-Sousa
Journal:  J Ophthalmol       Date:  2017-08-07       Impact factor: 1.909

7.  Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1.

Authors:  Chenlong Wang; Yaxin Chen; Yang Wang; Xiaoxiao Liu; Yanzhuo Liu; Ying Li; Honglei Chen; Chengpeng Fan; Dongfang Wu; Jing Yang
Journal:  J Exp Clin Cancer Res       Date:  2019-08-22

8.  Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway.

Authors:  Zhiyu Wang; Neng Wang; Shouwei Han; Dongmei Wang; Suilin Mo; Linzhong Yu; Hui Huang; Kamchuen Tsui; Jiangang Shen; Jianping Chen
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

9.  Isoliquiritigenin suppresses human T Lymphocyte activation via covalently binding cysteine 46 of IκB kinase.

Authors:  Fenggen Yan; Fen Yang; Rui Wang; Xiao Jun Yao; Liping Bai; Xing Zeng; JiaJun Huang; Vincent Kam Wai Wong; Christopher Wai Kei Lam; Hua Zhou; Xiaohui Su; Juan Liu; Ting Li; Liang Liu
Journal:  Oncotarget       Date:  2017-05-23

10.  Isoliquiritigenin attenuates spinal tuberculosis through inhibiting immune response in a New Zealand white rabbit model.

Authors:  Wenjing Wang; Baozhi Yang; Yong Cui; Ying Zhan
Journal:  Korean J Physiol Pharmacol       Date:  2018-06-25       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.